Get ready for the new EU JCA framework and understand what it means for your evidence strategy.

8 October 2026 | 2:00 PM CET | Online

About the Webinar

The EU Joint Clinical Assessment (JCA) is introducing a new approach to the clinical assessment of certain medical devices and in vitro diagnostics at European level.

But what does this mean in practice for manufacturers?

This webinar will provide a clear overview of the JCA framework and its practical implications, from the Joint Scientific Consultation (JSC) process to evidence scoping using the PICO framework.

The session will also explore how manufacturers can prepare early, anticipate evidence expectations and build an evidence strategy that supports both European-level assessment and national market access decisions.

What Will We Cover?

During this 90-minute webinar, we will explore:

• The JCA process and key timelines
• Joint Scientific Consultation (JSC)
• Evidence scoping and the PICO framework
• Key challenges manufacturers should anticipate
• Practical considerations for early evidence planning

The session will conclude with a live Q&A, giving participants the opportunity to discuss their questions directly with the experts.

Who Should Attend?

This webinar is particularly relevant for professionals working in:

Regulatory Affairs • Clinical Development • Market Access • HEOR • Medical Devices & IVDs • Health Technology Assessment

Speakers

Rachel Hoad
Director of Market Access, Lightning Health

Rachel holds a PhD in Cell Physiology and Pharmacology from the University of Leicester and a First-Class Undergraduate Masters degree in Molecular and Cellular Biology from the University of Bath.

Rachel has over a decade of experience in market access consultancy, working across pharmaceuticals, medical devices, drug-device combinations and digital health. Her therapy area expertise is varied and includes dermatology, rare diseases, oncology, HIV and NASH.

In a previous roles she has been responsible for providing strategic oversight to research projects to ensure overall objectives were met. She has extensive project experience that ranges from mapping and understanding the European market for medical devices and diagnostics, including TPP testing, product positioning, HTA and reimbursement landscapes, procurement routes and price potential.

Adam Ben Taied
Senior Consultant, Lightning Health

Adam Ben Taieb: Adam holds a First-Class Honours Degree in Biomedical Science from the University of Surrey, and an MSc in Science Communication from the University of Manchester. Adam has 7+ years experience working in the market access strategy and value communication field, working with pharmaceutical and medical device companies throughout their products lifecycle, to optimise their commercial potential, value and market access strategy.

Adam has experience in leading and delivering an extensive range projects, from early disease landscaping, pricing opportunity assessments and launch strategy development, through to evidence generation, value tools, HTA submissions, and stakeholder insights. His experience spans across numerous global markets as well as disease areas, including rare diseases, cardiology, neurology, respiratory, diabetes etc.

Practical Information

• Date: 8 October 2026
• Time: 2:00 PM CET
• Format: Online via Zoom
• Registration Fee: €15 for ICEPS members and 35€ for non-members (VAT excl.)
• Zoom Access: The Zoom link and connection details will be sent by email.
• Recording: The session will be recorded, and access to it will be only for ICEPS members

Important Information

Please note that this event is a live Question & Answer session only.

The purpose of the session is to provide clarification and discussion on the implementation of Estimands. Participants will have the opportunity to ask questions and exchange directly with the expert speaker.

This session is not a training course, and participation does not provide a certificate of attendance, training completion, or certification.

Your Zoom access link is personal and may not be shared. Any participant not registered through ICEPS may be removed from the webinar without notice.

Register now and join us to better understand the EU JCA landscape and prepare for what comes next.